These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 9438484)

  • 1. Discontinuation of yellow jacket venom immunotherapy: follow-up of 75 patients by means of deliberate sting challenge.
    van Halteren HK; van der Linden PW; Burgers JA; Bartelink AK
    J Allergy Clin Immunol; 1997 Dec; 100(6 Pt 1):767-70. PubMed ID: 9438484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis.
    van der Linden PW; Hack CE; Struyvenberg A; van der Zwan JK
    J Allergy Clin Immunol; 1994 Aug; 94(2 Pt 1):151-9. PubMed ID: 8064067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hymenoptera sting anaphylaxis and urticaria pigmentosa: clinical findings and results of venom immunotherapy in ten patients.
    Fricker M; Helbling A; Schwartz L; Müller U
    J Allergy Clin Immunol; 1997 Jul; 100(1):11-5. PubMed ID: 9257781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rush hymenoptera venom immunotherapy is efficacious and safe.
    Pasaoglu G; Sin BA; Misirligil Z
    J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clustered immunotherapy with Yellow Jacket venom. Evaluation of the influence of time interval on in vivo and in vitro parameters.
    Malling HJ; Djurup R; Søndergaard I; Weeke B
    Allergy; 1985 Jul; 40(5):373-83. PubMed ID: 4037258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of venom immunotherapy.
    Golden DB
    J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):703-4. PubMed ID: 9802387
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the risk of anaphylactic reactions by wasp venom-extract challenges in children.
    Schultze-Werninghaus C; Wahn U; Niggemann B
    Pediatr Allergy Immunol; 1999 May; 10(2):133-7. PubMed ID: 10478615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survey of patients after discontinuing venom immunotherapy.
    Golden DB; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 2000 Feb; 105(2 Pt 1):385-90. PubMed ID: 10669863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of immunotherapy with venom in children with allergy to insect stings.
    Valentine MD; Schuberth KC; Kagey-Sobotka A; Graft DF; Kwiterovich KA; Szklo M; Lichtenstein LM
    N Engl J Med; 1990 Dec; 323(23):1601-3. PubMed ID: 2098016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.
    Birnbaum J; Ramadour M; Magnan A; Vervloet D
    Clin Exp Allergy; 2003 Jan; 33(1):58-64. PubMed ID: 12534550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of an in-hospital insect sting challenge as a criterion for application or omission of venom immunotherapy.
    Blaauw PJ; Smithuis OL; Elbers AR
    J Allergy Clin Immunol; 1996 Jul; 98(1):39-47. PubMed ID: 8765816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stinging insect allergy: natural history and modification with venom immunotherapy.
    Reisman RE; Dvorin DJ; Randolph CC; Georgitis JW
    J Allergy Clin Immunol; 1985 Jun; 75(6):735-40. PubMed ID: 4008803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
    Gawlik R; Glück J; Jawor B; Rogala B
    Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
    Ruëff F; Wenderoth A; Przybilla B
    J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunologic follow-up of patients who stop venom immunotherapy.
    Keating MU; Kagey-Sobotka A; Hamilton RG; Yunginger JW
    J Allergy Clin Immunol; 1991 Sep; 88(3 Pt 1):339-48. PubMed ID: 1890261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous immunotherapy for hymenoptera venom allergy using six month intervals.
    Baenkler HW; Meusser-Storm S; Eger G
    Allergol Immunopathol (Madr); 2005; 33(1):7-14. PubMed ID: 15777517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Desensitization of allergy to hymenoptera venoms].
    Przybilla B; Ruëff F
    Wien Med Wochenschr; 1999; 149(14-15):421-8. PubMed ID: 10584286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.